Hrvatska znanstvena Sekcija img
3 gif
 O projektu
4 gif
Pregledavanje radova
Jednostavno pretraživanje
Napredno pretraživanje
Skupni podaci
Upis novih radova
Ispravci prijavljenih radova
Ostale bibliografije
Slični projekti
 Bibliografske baze podataka

Pregled bibliografske jedinice broj: 770684


Autori: Milić, Sandra; Mikolašević, Ivana; Krznarić-Zrnić, Irena; Stanić, Marija; Poropat, Goran; Štimac, Davor; Vlahović-Palčevski, Vera; Orlić, Lidija
Naslov: Nonalcoholic steatohepatitis: emerging targeted therapies to optimize treatment options
Izvornik: Drug Design Development and Therapy (1177-8881) 9 (2015); 4835-4845
Vrsta rada: pregledni rad
Ključne riječi: nonalcoholic fatty liver disease; nonalcoholic steatohepatitis; therapy
Diet and lifestyle changes have led to worldwide increases in the prevalences of obesity and metabolic syndrome, resulting in substantially greater incidence of nonalcoholic fatty liver disease (NAFLD). NAFLD is considered a hepatic manifestation of metabolic syndrome and is related to diabetes, insulin resistance (IR), central obesity, hyperlipidemia, and hypertension. Nonalcoholic steatohepatitis (NASH) is an entity that describes liver inflammation due to NAFLD. Growing evidence suggests that NAFLD is a multisystem disease with a clinical burden that is not only confined to liver-related morbidity and mortality, but that also affects several extra-hepatic organs and regulatory pathways. Thus, NAFLD is considered an important public health issue, but there is currently no effective therapy for all NAFLD patients in the general population. Studies seeking optimal therapy for NAFLD and NASH have not yet led to development of a universal protocol for treating this growing problem. Several pharmacological agents have been studied in an effort to improve IR and the pro-inflammatory mediators that may be responsible for NASH progression. Cardiovascular risk factors are highly prevalent among NASH patients, and the backbone of treatment regimens for these patients still comprises general lifestyle interventions, including dietary changes and increased physical activity. Vitamin E and thiazolidinedione derivatives are currently the most evidence-based therapeutic options, but only limited clinical evidence is available regarding their long-term efficacy and safety. Vitamin D and renin–angiotensin–aldosterone system blockers are promising drugs that are currently being intensively investigated for use in NAFLD/NASH patients.
Izvorni jezik: ENG
Rad je indeksiran u
bazama podataka:
Current Contents Connect (CCC)
Science Citation Index Expanded (SCI-EXP) (sastavni dio Web of Science Core Collectiona)
Kategorija: Znanstveni
Znanstvena područja:
Kliničke medicinske znanosti
URL Internet adrese:
Broj citata:
DOI: 10.2147/DDDT.S64877
URL cjelovitog teksta:
Google Scholar: Nonalcoholic steatohepatitis: emerging targeted therapies to optimize treatment options
Upisao u CROSBI: Sanjin Rački (, 22. Srp. 2015. u 16:06 sati

  Verzija za printanje   za tiskati